XML 29 R19.htm IDEA: XBRL DOCUMENT
v3.23.2

Earnings Per Share | 6 Months Ended
--- | ---
Jun. 30, 2023
Earnings Per Share [Abstract] |
Earnings per Share | 11. Earnings per Share Total outstanding shares as of June 30, 2023 and 2022, were 94.9 million and 94.2 million, respectively. Under our stock repurchase program, during each of the three and six months ended June 30, 2023, we did no t repurchase and retire any shares, and during each of the three and six months ended June 30, 2022, we repurchased and retired 2.7 million shares. For each of the six months ended June 30, 2023 and 2022, we acquired 0.3 million related to tax withholding for share-based compensation. The calculation of basic earnings per share of common stock is based on the weighted-average number of shares of common stock outstanding in the year, or period, over which they were outstanding. Our calculation of diluted earnings per share of common stock assumes that any shares of common stock outstanding were increased by shares that would be issued upon exercise of those stock awards for which the average market price for the period exceeds the exercise price less the shares that could have been purchased by the Company with the related proceeds, including compensation expense measured but not yet recognized. Our weighted-average number of shares outstanding for the three and six months ended June 30, 2023 and 2022 was as follows:
|  | Three months ended June 30, |  | Six Months Ended June 30,
(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022
Weighted-average number of shares of common stock outstanding - basic |  | 95.4 |  | 96.2 |  | 95.1 |  | 96.2
Restricted stock units |  | 0.9 |  | 1.2 |  | 1.6 |  | 1.8
Weighted-average shares and assumed conversions - diluted |  | 96.3 |  | 97.4 |  | 96.7 |  | 98.0
Awards of potentially dilutive shares of common stock, which have exercise prices that were higher than the average market price during the period, are not included in the computation of dilutive earnings per share as their effect would have been anti-dilutive. For the three and six months ended June 30, 2023, the number of anti-dilutive shares was approximately 10.4 million and 9.5 million, respectively. For each of the three and six months ended June 30, 2022, the number of anti-dilutive shares was approximately 10.2 million and 9.0 million, respectively.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration